三级aa视频在线观看-三级国产-三级国产精品一区二区-三级国产三级在线-三级国产在线

Global EditionASIA 中文雙語Fran?ais
World
Home / World / Europe

UK approves Novavax's jab for novel coronavirus

By ANGUS McNEICE in London | China Daily Global | Updated: 2022-02-08 10:04
Share
Share - WeChat
A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in front of displayed Novavax logo in this illustration taken, October 30, 2020. [Photo/Agencies]

The United Kingdom drug regulator has approved a COVID-19 vaccine from United States pharmaceutical company Novavax, becoming the fifth jab to get the green light in the UK, and the first protein-based shot to enter the market.

The UK Medicines and Healthcare products Regulatory Agency, or MHRA, granted regulatory approval for use in adults aged 18 and above, after the jab, which is called Nuvaxovid, was deemed safe and conferred 89.7 percent protection against infection in a phase-3 trial of 15,000 participants in Britain.

That study, which was published in the New England Journal of Medicine, followed on from a separate late-stage trial of 30,000 participants in the US and Mexico, which achieved 90.4 percent efficacy overall.

The UK has already ordered 60 million doses of the vaccine, which is administered in a two-dose regimen, 21 days apart.

"It is great to see our world-renowned medicines regulator approve another COVID-19 vaccine," said UK Health Secretary Sajid Javid. "The next step will be for the independent Joint Committee on Vaccination and Immunisation to consider its use as part of the UK COVID-19 vaccination program."

Nuvaxovid has gained approval in several countries over the last few months including South Africa, India, South Korea and Australia, and Novavax has submitted the treatment for approval to US regulators.

The company is poised to emerge as one of the largest distributors of COVID-19 vaccines in 2022, with plans to manufacture 2.44 billion doses. This would place it in the top five manufacturers this year, along with Pfizer (4.1 billion), Sinovac (1.88 billion), Sinopharm (1.85 billion) and AstraZeneca (1.75 billion), according to projections provided to China Daily by science consultancy Airfinity.

Novavax was bookmarked last year as one of the most promising COVID-19 treatments, following encouraging results in early trials. The jab has a long shelf life of nine months, and does not require ultracold storage. This makes the treatment ideal for distribution in the developing world, and the COVAX vaccine equity project reserved 350 million shots in May 2021.

However, development of the jab has been significantly delayed. Novavax is a relatively small company, and a number of supply and manufacturing issues pushed distribution back to 2022.

The shot from Novavax is the first protein-based COVID-19 vaccine to gain approval in the UK, and experts say that having different varieties of jabs is key to maintaining robust protection in populations against the novel coronavirus. Already in use in treatments for other diseases including Hepatitis B, the technology involves injecting a protein into the body that encourages an immune response, rather than introducing genetic material, as is the case in mRNA vaccines, or using inactivated virus, as seen in several currently available COVID-19 jabs.

June Raine, MHRA chief executive, said the approval followed a "rigorous review of the safety, quality and effectiveness of this vaccine".

Novavax said that serious side effects to the vaccine were low in clinical trials, and the most commonly-reported reactions included headache, nausea or vomiting, muscle pain, joint stiffness, injection site tenderness and fatigue.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 那一个欧美一级毛片 | 青青青视频蜜桃一区二区 | 国产精品亚洲一区二区三区在线播放 | 国产伦精品一区二区三区女 | 风间由美理伦片在线观看 | wwwa级片| 免费看黄色三级毛片 | 国产日韩视频在线 | 国产亚洲精品第一综合linode | 粉嫩jk制服美女啪啪 | 午夜激情福利网 | 久久精品国产99国产精品亚洲 | 艹逼视频免费 | 黄色三级影院 | 日本一级特黄毛片免费视频9 | 精品国产成人a在线观看 | 欧美ol丝袜高跟秘书在线播放 | 午夜性刺激免费视频 | 大尺度做爰视频吃奶www | a级午夜毛片免费一区二区 a级午夜理论免费毛片 | 亚洲欧美日韩一区二区在线观看 | aaaaaa级特色特黄的毛片 | 欧美三级真做在线观看 | baoyu在线观看地址 | 九九精品免费观看在线 | 乱人伦99久久 | 亚洲特黄| 亚洲成人7777 | 国内精品久久影视免费 | 免费观看黄a一级视频 | 亚洲女同视频 | 一区二区三区在线播放 | 国产精品成人h片在线 | 6969精品视频在线观看 | 麻豆传媒入口直接进入免费版 | 婷婷色婷婷 | 香蕉爱视频 | 黄色影片在线观看 | 337日本| 特级做人爱c欧美网站 | 国产精品真实对白精彩久久 |